AcuCort AB (publ) announced that the Canadian Intellectual Property Office, CIPO, has granted a patent for AcuCort's drug Zeqmelit™. The patent protection covers the oral film technology with steroids that enables a user-friendly form of administration for the patient. The positive decision from the Canadian Intellectual Property Office means that the oral film technology with steroids used in AcuCort's approved drug Zeqmelit™ has patent protection.

The drug's name was formerly ISICORT. The Canadian patent is co-owned with AcuCort's former manufacturing partner LTS Lohmann. Intellectual property rights such as patent and trademark protection play a crucial role in AcuCort's future commercial opportunities.

The company has an active IP strategy covering the important pharmaceutical markets. Zeqmelit™ currently has patent protection in more than 30 countries, including Europe, the U.S., Japan, China and Canada. In the development of Zeqmelit™, AcuCort has managed to combine the benefits of the well-proven substance dexamethasone and the patented user-friendly oral film for quick availability and relief in emergency situations such as severe and acute allergic reactions.

Zeqmelit™ is approved in Sweden, Denmark and Norway. The registration process for other countries within the EU is ongoing. AcuCort's overarching goal is to commercialize Zeqmelit™ globally, i.e. in the EU, the U.S. and in other priority markets.